Kairos Pharma Ltd KAPA
$0.29 $0.01 (1.73%) 1D
Last Updated: Aug 21, 12:00 AM·XASE
Pricing for US stocks is delayed by 24 hours
KAPA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Kairos Pharma Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Kairos Pharma Ltd. Stock Analysis KAPA
United States Health Care Nano Cap Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The firm is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.
Kairos Pharma Ltd (KAPA) Chart
Financial Metrics & Statements of Kairos Pharma Ltd (KAPA)
FAQ's for Kairos Pharma Ltd (KAPA)
- As of August 2026, Kairos Pharma Ltd KAPA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kairos Pharma Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kairos Pharma Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kairos Pharma Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kairos Pharma Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kairos Pharma Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Kairos Pharma Ltd (KAPA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
